KR100592193B1 - 글리시리진산과 항바이러스 활성을 갖는 적어도 하나의 단백질로 이루어진 항바이러스성 제약 조성물 - Google Patents

글리시리진산과 항바이러스 활성을 갖는 적어도 하나의 단백질로 이루어진 항바이러스성 제약 조성물 Download PDF

Info

Publication number
KR100592193B1
KR100592193B1 KR1019997010372A KR19997010372A KR100592193B1 KR 100592193 B1 KR100592193 B1 KR 100592193B1 KR 1019997010372 A KR1019997010372 A KR 1019997010372A KR 19997010372 A KR19997010372 A KR 19997010372A KR 100592193 B1 KR100592193 B1 KR 100592193B1
Authority
KR
South Korea
Prior art keywords
lysozyme
lactoferrin
antiviral
acid
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997010372A
Other languages
English (en)
Korean (ko)
Other versions
KR20010012419A (ko
Inventor
폼페이라파엘로
핀자마리오
Original Assignee
아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 filed Critical 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이
Publication of KR20010012419A publication Critical patent/KR20010012419A/ko
Application granted granted Critical
Publication of KR100592193B1 publication Critical patent/KR100592193B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019997010372A 1997-05-14 1998-05-06 글리시리진산과 항바이러스 활성을 갖는 적어도 하나의 단백질로 이루어진 항바이러스성 제약 조성물 Expired - Fee Related KR100592193B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI97A001119 1997-05-14
IT97MI001119A IT1291366B1 (it) 1997-05-14 1997-05-14 Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale
PCT/EP1998/002797 WO1998051334A1 (en) 1997-05-14 1998-05-06 Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity

Publications (2)

Publication Number Publication Date
KR20010012419A KR20010012419A (ko) 2001-02-15
KR100592193B1 true KR100592193B1 (ko) 2006-06-23

Family

ID=11377123

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997010372A Expired - Fee Related KR100592193B1 (ko) 1997-05-14 1998-05-06 글리시리진산과 항바이러스 활성을 갖는 적어도 하나의 단백질로 이루어진 항바이러스성 제약 조성물

Country Status (26)

Country Link
US (1) US6329339B1 (cg-RX-API-DMAC7.html)
EP (1) EP0980254B1 (cg-RX-API-DMAC7.html)
JP (2) JP2001525814A (cg-RX-API-DMAC7.html)
KR (1) KR100592193B1 (cg-RX-API-DMAC7.html)
CN (1) CN1114447C (cg-RX-API-DMAC7.html)
AR (1) AR012849A1 (cg-RX-API-DMAC7.html)
AT (1) ATE212232T1 (cg-RX-API-DMAC7.html)
AU (1) AU740944B2 (cg-RX-API-DMAC7.html)
BG (1) BG64748B1 (cg-RX-API-DMAC7.html)
CA (1) CA2289550A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ291932B6 (cg-RX-API-DMAC7.html)
DE (1) DE69803565T2 (cg-RX-API-DMAC7.html)
DK (1) DK0980254T3 (cg-RX-API-DMAC7.html)
EA (1) EA003126B1 (cg-RX-API-DMAC7.html)
ES (1) ES2170501T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20022672B (cg-RX-API-DMAC7.html)
HU (1) HU224956B1 (cg-RX-API-DMAC7.html)
IL (2) IL132651A0 (cg-RX-API-DMAC7.html)
IT (1) IT1291366B1 (cg-RX-API-DMAC7.html)
PL (1) PL189218B1 (cg-RX-API-DMAC7.html)
PT (1) PT980254E (cg-RX-API-DMAC7.html)
SK (1) SK283584B6 (cg-RX-API-DMAC7.html)
TR (1) TR199902730T2 (cg-RX-API-DMAC7.html)
UA (1) UA63955C2 (cg-RX-API-DMAC7.html)
WO (1) WO1998051334A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA983917B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
EP1499341A4 (en) * 2002-04-18 2010-10-27 Univ Iowa Res Found METHOD FOR INHIBITING AND TREATING BACTERIAL BIOFILMS WITH METAL CHELATE IMAGES
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
AU2004272607B2 (en) * 2003-09-11 2008-11-06 Cornerstone Therapeutics Inc. Monoclonal antibodies against HMGB1
WO2007011606A2 (en) * 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
US20080311122A1 (en) * 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
IT1391170B1 (it) * 2008-08-07 2011-11-18 D M G Italia S R L Composizione topica intra-nasale utilizzabile in caso di ostruzione nasale
CA2809031C (en) * 2010-08-25 2018-10-16 Weijian Zhang Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
US9416151B2 (en) 2010-08-25 2016-08-16 Lurong ZHANG Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
CN106029089B (zh) * 2014-02-21 2020-12-29 丘比株式会社 诺如病毒灭活剂及其制造方法
US12594285B2 (en) 2016-02-25 2026-04-07 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP3419629A4 (en) * 2016-02-25 2019-10-30 Applied Biological Laboratories, Inc. COMPOSITIONS AND PROCEDURES FOR PROTECTION AGAINST AIRBORNE PATHOGENES AND IRRITATES
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
CN109022351B (zh) * 2018-09-28 2021-10-19 广州奇龙生物科技有限公司 重组人溶菌酶的新应用
CN112135625B (zh) * 2020-04-27 2021-07-06 广州新创忆药物临床研究有限公司 一种预防或治疗covid-19新冠肺炎的药物及其应用
MX2021005280A (es) * 2021-05-04 2022-02-23 Spv Timser S A P I De C V Composicion farmaceutica que contiene triterpenoides pentaciclicos.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275457A2 (en) * 1986-12-19 1988-07-27 Eisai Co., Ltd. Solution containing lysozyme hydrochloride and dipotassium glycyrrhizinate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2838720B2 (ja) * 1989-10-31 1998-12-16 ゼリア新薬工業株式会社 安定な点眼剤
JP4056099B2 (ja) * 1996-05-09 2008-03-05 森永乳業株式会社 水生動物の寄生生物性疾患の予防および治療剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0275457A2 (en) * 1986-12-19 1988-07-27 Eisai Co., Ltd. Solution containing lysozyme hydrochloride and dipotassium glycyrrhizinate

Also Published As

Publication number Publication date
ZA983917B (en) 1998-11-09
TR199902730T2 (xx) 2000-02-21
EA003126B1 (ru) 2003-02-27
HUP0002985A3 (en) 2001-04-28
JP2009102370A (ja) 2009-05-14
CN1114447C (zh) 2003-07-16
CZ399199A3 (cs) 2000-04-12
AR012849A1 (es) 2000-11-22
GEP20022672B (en) 2002-04-25
CZ291932B6 (cs) 2003-06-18
DK0980254T3 (da) 2002-05-06
IT1291366B1 (it) 1999-01-07
PL336802A1 (en) 2000-07-17
SK283584B6 (sk) 2003-10-07
KR20010012419A (ko) 2001-02-15
US6329339B1 (en) 2001-12-11
IL132651A (en) 2006-10-31
CA2289550A1 (en) 1998-11-19
ES2170501T3 (es) 2002-08-01
EP0980254A1 (en) 2000-02-23
HU224956B1 (en) 2006-04-28
UA63955C2 (uk) 2004-02-16
WO1998051334A1 (en) 1998-11-19
IL132651A0 (en) 2001-03-19
DE69803565T2 (de) 2002-08-08
PT980254E (pt) 2002-07-31
PL189218B1 (pl) 2005-07-29
HUP0002985A2 (hu) 2001-01-29
AU740944B2 (en) 2001-11-15
AU7764698A (en) 1998-12-08
CN1255859A (zh) 2000-06-07
ITMI971119A1 (it) 1998-11-14
BG103968A (en) 2000-07-31
HK1028347A1 (en) 2001-02-16
EA199901024A1 (ru) 2000-06-26
ITMI971119A0 (cg-RX-API-DMAC7.html) 1997-05-14
BG64748B1 (bg) 2006-02-28
DE69803565D1 (de) 2002-03-14
JP2001525814A (ja) 2001-12-11
EP0980254B1 (en) 2002-01-23
SK154499A3 (en) 2000-08-14
ATE212232T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
US6329339B1 (en) Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity
CA1254510A (en) Fibronectin preparations
US6638909B1 (en) Wound healing compositions containing alpha-1-antitrypsin
CN111529685A (zh) 抗呼吸道病毒感染的鼻腔喷雾制剂
CA2293470A1 (en) Benzimidazole derivatives
US9149514B2 (en) Composition and method for treating papilloma virus and equine sarcoids
CA2135614A1 (en) Use of urodilatin in pulmonary and bronchial diseases
KR102538216B1 (ko) 폴리감마글루탐산을 유효성분으로 포함하는 코로나바이러스(SARS-CoV-2) 감염질환의 예방, 경감 또는 치료용 약학적 조성물
KR20200052310A (ko) 합성 라이신 유사체 및 모방체의 항바이러스 용도를 위한 방법 및 조성물
EP0128009B1 (en) Synergistic composition comprising gamma interferon and lymphotoxin, and its preparation
JPS6237615B2 (cg-RX-API-DMAC7.html)
US4828830A (en) Method and composition for prophylaxis and treatment of viral infections
MXPA99010447A (en) Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity
US5849282A (en) Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser71 !-interleukin-1β
HK1028347B (en) Pharmaceutical antiviral composition comprising glycyrrhizic acid and at least one protein endowed with antiviral activity
Tsan et al. D-factor and growth hormone enhance tumor necrosis factor-induced increase of mn superoxide dismutase mrna and oxygen tolerance
GB2168608A (en) Interferon compositions for treatment of rhinovirus infections
CA2193665A1 (en) Benzimidazole derivatives for the treatment and prophylaxis of virus infections

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20090616

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20090616

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301